Compare NBIX & RNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBIX | RNR |
|---|---|---|
| Founded | 1992 | 1993 |
| Country | United States | Bermuda |
| Employees | N/A | 1040 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2B | 12.8B |
| IPO Year | 1996 | N/A |
| Metric | NBIX | RNR |
|---|---|---|
| Price | $130.61 | $307.76 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 22 | 14 |
| Target Price | $180.82 | ★ $314.75 |
| AVG Volume (30 Days) | ★ 901.1K | 229.6K |
| Earning Date | 05-04-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 0.52% |
| EPS Growth | ★ 41.95 | N/A |
| EPS | ★ 4.67 | N/A |
| Revenue | ★ $161,626,000.00 | N/A |
| Revenue This Year | $22.85 | N/A |
| Revenue Next Year | $10.36 | $2.96 |
| P/E Ratio | $27.09 | ★ $5.42 |
| Revenue Growth | ★ 977.51 | N/A |
| 52 Week Low | $97.30 | $222.75 |
| 52 Week High | $160.18 | $315.88 |
| Indicator | NBIX | RNR |
|---|---|---|
| Relative Strength Index (RSI) | 50.14 | 60.98 |
| Support Level | $124.29 | $288.11 |
| Resistance Level | $136.23 | $312.68 |
| Average True Range (ATR) | 4.29 | 6.78 |
| MACD | -0.08 | 1.18 |
| Stochastic Oscillator | 59.64 | 75.51 |
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
RenaissanceRe Holdings Ltd provides reinsurance and insurance solutions and related services. The company's core products include property, casualty and specialty reinsurance. Revenue is derived from three sources: net premiums earned from the insurance and insurance products sold; net investment income from the investment of capital funds and cash; and other income from the company's joint ventures, advisory services, and other items. The reportable segments of the company are the Property segment which includes catastrophe and other property reinsurance, and the Casualty and Specialty segment which is comprised of casualty and specialty reinsurance. It derives a majority of its revenue from the Casualty and specialty segment.